RESUMO
Major bacterial infections are most commonly associated with agranulocytosis or an abnormality of immunoglobulins or complement. Occasionally, repeated infections cannot be attributed to these relatively common causes. In such cases, a quantitative abnormality in neutrophil function should be sought. Complete evaluation of neutrophil function, including: chemotaxis, adhesion, aggregation, phagocytosis, granule content and degranulation, respiratory burst activity and bacterial killing is expensive and requires the services of a specialized laboratory. However, preliminary screening of a patient with a predisposition towards infection can be carried out using simple and inexpensive methods. These include examination of blood films, chemotaxis assay, NBT test and peroxidase staining. For final diagnosis and determination of genetic transmission and treatment, specific tests are indicated. Investigation of neutrophil functions may be useful for the diagnosis of congenital and acquired neutrophil disorders. These assays may also be useful in research, diagnosis and follow up of non-infectious diseases with active inflammatory component.
Assuntos
Infecções Bacterianas/sangue , Deficiência de Glucosefosfato Desidrogenase/sangue , Doença Granulomatosa Crônica/sangue , Doenças Hematológicas/sangue , Neutrófilos/fisiologia , Doença Granulomatosa Crônica/diagnóstico , Doença Granulomatosa Crônica/terapia , Humanos , Síndrome da Aderência Leucocítica Deficitária/sangue , Peroxidase/deficiência , RecidivaRESUMO
The surface antigen (S) gene promoter, one of the major hepatitis B virus (HBV) promoters, directs the synthesis of a 2.1 kb mRNA which encodes the preS2 and S polypeptides. The preS2/S promoter does not contain a classical TATA box, and transcription regulation of the preS2/S gene has not been fully elucidated. We analysed two regions involved in preS2/S gene transcription of the HBV adw subtype: the diverged TATA box and a putative initiator element. We demonstrated sequence specific promoter activity of the putative TATA-like sequences in the preS2/S gene promoter (-25 to -32 bp). Using end labeled synthetic oligonucleotides we observed specific binding of nuclear extracts to the diverged TATA sequence, that was significantly reduced using a mutated oligonucleotide. Specific binding of yeast TBP to the diverged TATA sequence was shown which was increased in the mutant containing a classical TATA box. We analysed the proposed initiator (Inr) sequence of the preS2/S promoter region (-13 to -16 bp). Deletion of the inr element markedly reduced promoter activity as assessed by CAT expression. Gel shift assays showed specific binding of nuclear extracts to wild type but not to mutant Inr. Expression studies with double mutants of the diverged TATA and the Inr element established that both elements are active in transcription regulation.
Assuntos
Proteínas de Ligação a DNA/metabolismo , Antígenos de Superfície da Hepatite B/genética , Vírus da Hepatite B/genética , Regiões Promotoras Genéticas , Fatores de Transcrição/metabolismo , Sequência de Bases , Sítios de Ligação , Carcinoma Hepatocelular , Cloranfenicol O-Acetiltransferase/biossíntese , Clonagem Molecular , DNA Viral/química , DNA Viral/metabolismo , Variação Genética , Antígenos de Superfície da Hepatite B/biossíntese , Humanos , Neoplasias Hepáticas , Dados de Sequência Molecular , Proteínas Recombinantes de Fusão/biossíntese , Proteínas Recombinantes/metabolismo , TATA Box , Proteína de Ligação a TATA-Box , Transfecção , Células Tumorais CultivadasRESUMO
Intravascular lymphomatosis (IVL) is a rare malignancy characterized by neoplastic proliferation of lymphoid cells within the lumens of arteries, small veins and capillaries. We report four patients with IVL and review the recent world literature, relating to incidence, clinical features and possible therapy. In these cases diagnosis was established coincidentally in one patient after prostatectomy. This patient eventually had central nervous system involvement. In two other patients IVL was diagnosed from skin lesions. In the fourth case the diagnosis was established at post-mortem examination, where involvement of most organs was evident but particularly kidneys, myocardium, gastrointestinal tract and lymph nodes. Therapy was given to three patients, but the disease progressed in two and they both died with evidence of central nervous system involvement, while the third patient has had a good partial response to combination chemotherapy but has relapsed within two months of completing chemotherapy. As evident from our patients and the literature review IVL has a variable clinical course and currently, there appears to be no effective therapy for this rare disorder.
Assuntos
Linfoma não Hodgkin/patologia , Neoplasias Vasculares/patologia , Idoso , Artrite Reumatoide/complicações , Artrite Reumatoide/tratamento farmacológico , Asma/complicações , Asma/tratamento farmacológico , Sedimentação Sanguínea , Medula Óssea/patologia , Neoplasias Encefálicas/diagnóstico , Neoplasias Encefálicas/patologia , Progressão da Doença , Eritema/etiologia , Evolução Fatal , Feminino , Febre de Causa Desconhecida/etiologia , Humanos , Hospedeiro Imunocomprometido , Imunofenotipagem , Imunossupressores/efeitos adversos , Imunossupressores/uso terapêutico , Linfoma de Células B/diagnóstico , Linfoma de Células B/patologia , Linfoma não Hodgkin/diagnóstico , Masculino , Prednisona/efeitos adversos , Prednisona/uso terapêutico , Prostatectomia , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/patologia , Coxa da Perna , Neoplasias Vasculares/diagnósticoRESUMO
This prospective study was designed to explore the prevalence and the clinical and prognostic significance of anticardiolipin (ACL) antibodies in patients with acute myeloid leukemia (AML). The study includes 37 consecutive AML patients >15 years old without previous history of thromboembolism, recurrent fetal loss, or autoimmune disease and with no evidence of infection at the time of enrollment. ACL antibodies were found in 25 patients (68%). None of the patients had high positive titers; 8 had moderately positive while 17 had low positive ACL antibody titers. ACL antibody positivity did not predict response to chemotherapy and was not correlated with age, gender, FAB class, platelet and white blood cell counts at presentation, and the risk of thromboembolism. ACL antibody titers did correlate, however, with AML activity in the majority of patients (93%) during 4-19 months of follow up. These results demonstrate a high prevalence of ACL antibodies in AML patients and suggest that serum ACL antibodies may be a useful adjunct in predicting relapse and documenting disease activity and therapy response.
Assuntos
Anticorpos Anticardiolipina/sangue , Biomarcadores Tumorais , Leucemia Mieloide/imunologia , Doença Aguda , Adolescente , Adulto , Idoso , Feminino , Humanos , Leucemia Mieloide/sangue , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos TestesRESUMO
We observed two patients with systemic paresthesia as the sole systemic manifestation of envenomation by L. quinquestriatus. A prospective study of the incidence of local and systemic paresthesia in 20 consecutive patients stung by this scorpion was done. Sixteen patients (80%) had only local complaints and 4/20 (20%) had mild systemic manifestations. Eleven patients (55%) had local paresthesia and in 2 patients (10%) systemic paresthesia was noted involving all four extremities in one patient and the perioral area in the other. The possible mechanism of paresthesia following a scorpion sting is discussed.
Assuntos
Parestesia/etiologia , Picadas de Escorpião/fisiopatologia , Venenos de Escorpião/intoxicação , Adulto , Animais , Criança , Feminino , Humanos , Israel/epidemiologia , Masculino , Pessoa de Meia-Idade , Parestesia/epidemiologia , Parestesia/fisiopatologia , Prevalência , Estudos Prospectivos , Picadas de Escorpião/epidemiologia , EscorpiõesRESUMO
Ischemic hepatitis, a relatively infrequent disorder occurring in 0.16% to 0.50% of patients admitted to medical intensive care units, often follows episodes of hypotension or acute heart failure. Investigating the clinical characteristics of patients with ischemic hepatitis may add to our understanding of the pathogenesis and significance of this syndrome. We therefore conducted a retrospective analysis of 34 patients to examine the possible contribution of the various baseline characteristics to the severity of the hepatic damage. In all patients liver disease was unexpected and in some, liver dysfunction dominated the clinical picture. All patients had high serum glutamic pyruvic transaminase (SGPT) and lactic dehydrogenase (LDH) levels (mean +/- SE, 2073 +/- 255 international units and 6085 +/- 748 international units, respectively). The mean SGPT/LDH ratio was 0.34. Most patients had coagulopathy with a prolonged prothrombin time (mean +/- SE, 5.86 +/- 1.37 international normalized ratio [INR]). The most common diagnosis on admission was respiratory distress secondary to various causes. Before the development of the hepatic dysfunction, respiratory failure and hypoxemia were observed in 68% of the patients, whereas hypotension was observed in only 38%. More than 90% of the patients had three or more associated comorbid conditions. The most frequent of these were left heart failure (88.2%), right heart failure (67.6%), chronic obstructive lung disease (58.8%), and chronic renal failure (55.9%). During the acute episode, more than 90% of the patients had transient deterioration of their renal functions. Hypoglycemia was noted in 11 patients (32.4%), and the glucose level was inversely correlated with the SGPT level (r = -0.43, p = 0.01). Stepwise multiple regression analysis showed that left heart failure, systolic blood pressure lower than 90 mm Hg, and female gender, together, accounted for 34% of the variance of the peak SGPT levels (p = 0.002). Fourteen (41.2%) patients died during the 3-month follow-up period, but none from the hepatic injury. None of the clinical or laboratory parameters measured predicted mortality. Clearly, ischemic hepatitis is associated with a high risk of death. The characteristic patients are those with multiple underlying systemic diseases and conditions, especially those with left heart failure. Liver function test results and levels of liver enzymes should be monitored in these patients, particularly when they are admitted for respiratory deterioration and episodes of hypotension.
Assuntos
Hepatite/etiologia , Isquemia/etiologia , Testes de Função Hepática , Fígado/irrigação sanguínea , Doença Aguda , Idoso , Idoso de 80 Anos ou mais , Diagnóstico Diferencial , Feminino , Hepatite/diagnóstico , Hepatite/mortalidade , Humanos , Isquemia/diagnóstico , Isquemia/patologia , Masculino , Pessoa de Meia-Idade , Prognóstico , Taxa de SobrevidaRESUMO
Hepatitis C virus (HCV) has nucleotide sequence diversity distributed throughout the viral genome, with variants showing even less than 70% homology. There is some evidence that sequence variation of HCV genotypes partly determines the course of infection and response to treatment with interferon. We studied the sera of 29 Israeli HCV patients, all suffering from chronic liver disease, and 34 patients with renal failure necessitating hemodialysis. HCV genotypes were detected using a reverse hybridization assay (LiPA), after reverse transcription polymerase chain reaction, using primers spanning the 5' UTR of the HCV genome. In this preliminary report the predominant HCV type detected was type 1, found in 65% of the chronic hepatitis patients and in 88% of the hemodialysis patients. Subtype 1b was the most prevalent and was detected in >40% of the chronic hepatitis patients and in >70%of the dialysis patients. Other types detected were 2a and 3, and in only two patients was type 4 found. More than 50% of patients with type 1 (1a or 1b) among patients with chronic hepatitis had received blood transfusion in the past, but only 16.6% of patients bearing subtype 2a HCV had such a history. Our preliminary evaluation revealed that patients bearing subtype 1b seemed to have a better response to interferon treatment, as compared with patients infected with subtypes 1a, 2a, who displayed a low response rate.
Assuntos
Hepacivirus/efeitos dos fármacos , Hepacivirus/genética , Hepatite C/tratamento farmacológico , Interferons/uso terapêutico , Adulto , Doença Crônica , Feminino , Genótipo , Humanos , Masculino , Reação em Cadeia da Polimerase/métodos , DNA Polimerase Dirigida por RNA , Resultado do TratamentoRESUMO
Sinus histiocytosis with massive lymphadenopathy (SHML)-Rosai-Dorfman disease-is a rare but well-defined benign histiocytic proliferative disorder. We report an unusual patient, cured of non-Hodgkin's lymphoma, who presented 12 years later with renotesticular SHML associated with IgA monoclonal gammopathy, but without any evidence of relapsed lymphoma. The genitourinary manifestations of this disorder with massive lymphadenopathy and its rare association with malignant lymphoma are reviewed.
Assuntos
Histiocitose Sinusal/etiologia , Adulto , Idoso , Criança , Histiocitose Sinusal/diagnóstico , Humanos , Técnicas Imunoenzimáticas , Nefropatias/etiologia , Linfoma não Hodgkin/terapia , Masculino , Pessoa de Meia-Idade , Doenças Testiculares/etiologia , Testículo/patologia , Fatores de TempoRESUMO
Israel has no official prevention policy at present against perinatal and horizontal transmission of hepatitis B virus (HBV) infection in newborns and children at risk. The present study was designed to assess the prevalence of HBV carrier state in a population of 11,123 pregnant women at term. Among this population (mean age 29.7 +/- 5.9), 98 women (0.88%) were found to be asymptomatic HBsAg+ carriers, and 97% of these carriers were anti-HBe+. Evidence for HBV replication, as determined by serum HBV-DNA, was established in 6.6% of the HBsAg+/anti-HBe+ population. The HBsAg carrier rate was strongly influenced by religion, continent, and country of birth of the carrier mothers. The highest relative carrier rate was found among women of Moslem origin (4.3%), as compared to Jewish women (0.67%). Most carrier women were born in Israel (56.1%) to mothers who had emigrated from regions with intermediate or high endemicity of HBV, such as North Africa or the Middle East. In these groups, the HBsAg carrier rate ranged between 1.2 and 3.0%. Ninety-three percent of newborns receiving passive/active vaccination against HBV developed protective levels of anti-HBs. Finally, evidence for horizontal transmission of HBV was found in 19.3% of 83 non-vaccinated children in families of HBsAg carriers. The present study therefore establishes HBsAg prevalence rates in specific risk groups of women at term and confirms the need for an official policy on immunization against HBV in Israel. Since over 50% of women at term belong to the defined risk groups, universal active vaccination of the entire newborn population each year is suggested as the most rational and needed policy in Israel.